Generic Truqap Availability

Last updated on Apr 10, 2025.

Truqap is a brand name of capivasertib, approved by the FDA in the following formulation(s):

TRUQAP (capivasertib - tablet;oral)

Manufacturer: ASTRAZENECA
Approval date: November 16, 2023
Strength(s): 160MG ^[RLD], 200MG ^[RLD]

Is there a generic version of Truqap available?

No. There is currently no therapeutically equivalent version of Truqap available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Truqap. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide
Patent 10,039,766
Issued: August 7, 2018
Inventor(s): Tomkinson Gary Peter
Assignee(s): AstraZeneca AB
The present invention discloses certain new solid state forms of (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, processes for preparing such forms, pharmaceutical compositions comprising them, and the use of such forms in therapy.
Patent expiration dates:
- April 16, 2033
  ✓
  Patent use: TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY
Protein kinase B inhibitors
Patent 10,059,714
Issued: August 28, 2018
Inventor(s): Johnson Paul David & Leach Andrew & Luke Richard William Arthur & Matusiak Zbigniew Stanley & Morris Jeffrey James
Assignee(s): AstraZeneca AB
The invention relates to a novel group of compounds of Formula (I) or salts thereof:
Patent expiration dates:
- October 10, 2028
  ✓
  Drug substance
  ✓
  Drug product
Protein kinase B inhibitors
Patent 10,654,855
Issued: May 19, 2020
Inventor(s): Johnson Paul David & Leach Andrew & Luke Richard William Arthur & Matusiak Zbigniew Stanley & Morris Jeffrey James
Assignee(s): AstraZeneca AB
The invention relates to a novel group of compounds of Formula (I) or salts thereof:
Patent expiration dates:
- October 10, 2028
  ✓
  Patent use: TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY
Protein kinase B inhibitors
Patent 11,760,760
Issued: September 19, 2023
Inventor(s): Johnson; Paul David et al.
Assignee(s): AstraZeneca AB (Södertälje, SE)
The invention relates to a novel group of compounds of Formula (I) or salts thereof: ##STR00001##
wherein Y, Z.sup.1, Z.sup.2, R.sup.1, R.sup.4, R.sup.5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
Patent expiration dates:
- October 10, 2028
  ✓
  Patent use: TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY
Protein kinase B inhibitors
Patent 12,252,495
Issued: March 18, 2025
Inventor(s): Johnson; Paul David et al.
Assignee(s): ASTRAZENECA AB (Södertälje, SE)
The invention relates to a novel group of compounds of Formula (I) or salts thereof: ##STR00001##
wherein Y, Z.sup.1, Z.sup.2, R.sup.1, R.sup.4, R.sup.5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
Patent expiration dates:
- October 10, 2028
  ✓
  Patent use: TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY
Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor
Patent 8,101,623
Issued: January 24, 2012
Inventor(s): Luke Richard William Arthur & Matusiak Zbigniew Stanley
Assignee(s): AstraZeneca AB
The invention relates to a novel group of compounds of Formula (I) or salts thereof:
Patent expiration dates:
- March 10, 2030
  ✓
  Patent use: TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY
  ✓
  Drug substance
  ✓
  Drug product
Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors
Patent 8,809,336
Issued: August 19, 2014
Inventor(s): Berdini; Valerio et al.
Assignee(s): Astex Therapeutics Limited (Cambridge, GB); The Institute of Cancer Research: Royal Cancer Hospital (London, GB); Cancer Research Technology Limited (London, GB)
The invention provides a compound for use as a protein kinase B inhibitor, the compound being a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR.sup.5; J.sup.1-J.sup.2 is N.dbd.C(R.sup.6), (R.sup.7)C.dbd.N, (R.sup.8)N--C(O), (R.sup.8).sub.2C--C(O), N.dbd.N or (R.sup.7)C.dbd.C(R.sup.6); E is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up to 3 heteroatoms selected from O, N and S; Q.sup.1 is a bond or a saturated C.sub.1-3 hydrocarbon linker group, one of the carbon atoms in the linker group being optionally be replaced by an oxygen or nitrogen atom, or an adjacent pair of carbon atoms may be replaced by CONR.sup.q or NR.sup.qCO where R.sup.q is hydrogen or methyl, or R.sup.q is a C.sub.1-4 alkylene chain linked to R.sup.1 or a carbon atom of Q.sup.1 to form a cyclic moiety; and wherein the carbon atoms of the linker group Q.sup.1 may optionally bear one or more substituents selected from fluorine and hydroxy; Q.sup.2 is a bond or a saturated hydrocarbon linker group containing from 1 to 3 carbon atoms, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group may optionally bear one or more substituents selected from fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the G group; and provided that when E is aryl or heteroaryl, then Q.sup.2 is other than a bond; G is hydrogen, NR.sup.2R.sup.3, OH or SH provided that when E is aryl or heteroaryl and Q.sup.2 is a bond, then G is hydrogen; R.sup.1 is hydrogen or an aryl or heteroaryl group, with the proviso that when R.sup.1 is hydrogen and G is NR.sup.2R.sup.3, then Q.sup.2 is a bond; and R.sup.2, R.sup.3, R.sup.4, R.sup.6 and R.sup.8 are as defined in the claims. ##STR00001##
Patent expiration dates:
- October 25, 2025
  ✓
  Patent use: TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY
Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein
Patent 9,006,430
Issued: April 14, 2015
Inventor(s): Berdini; Valerio et al.
Assignee(s): Astex Therapeutics Limited (Cambridge, GB); The Institute of Cancer Research: Royal Cancer Hospital (London, GB); Cancer Research Technology Limited (London, GB)
The invention provides a compound for use as a protein kinase B inhibitor, the compound being a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR.sup.5; J.sup.1-J.sup.2 is N.dbd.C(R.sup.6), (R.sup.7)C.dbd.N, (R.sup.8)N--C(O), (R.sup.8).sub.2C--C(O), N.dbd.N or (R.sup.7)C.dbd.C(R.sup.6); E is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up to 3 heteroatoms selected from O, N and S; Q.sup.1 is a bond or a saturated C.sub.1-3 hydrocarbon linker group, one of the carbon atoms in the linker group being optionally be replaced by an oxygen or nitrogen atom, or an adjacent pair of carbon atoms may be replaced by CONR.sup.q or NR.sup.qCO where R.sup.q is hydrogen or methyl, or R.sup.q is a C.sub.1-4 alkylene chain linked to R or a carbon atom of Q.sup.1 to form a cyclic moiety; and wherein the carbon atoms of the linker group Q.sup.1 may optionally bear one or more substituents selected from fluorine and hydroxy; Q.sup.2 is a bond or a saturated hydrocarbon linker group containing from 1 to 3 carbon atoms, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group may optionally bear one or more substituents selected from fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the G group; and provided that when E is aryl or heteroaryl, then Q.sup.2 is other than a bond; G is hydrogen, NR.sup.2R.sup.3, OH or SH provided that when E is aryl or heteroaryl and Q.sup.2 is a bond, then G is hydrogen; R.sup.1 is hydrogen or an aryl or heteroaryl group, with the proviso that when R.sup.1 is hydrogen and G is NR.sup.2R.sup.3, then Q is a bond; and R.sup.2, R.sup.3, R.sup.4, R.sup.6 and R.sup.8 are as defined in the claims. ##STR00001##
Patent expiration dates:
- October 25, 2025
  ✓
  Drug product
Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide
Patent 9,487,525
Issued: November 8, 2016
Inventor(s): Tomkinson Gary Peter
Assignee(s): AstraZeneca AB
The present invention discloses certain new solid state forms of (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, processes for preparing such forms, pharmaceutical compositions comprising them, and the use of such forms in therapy.
Patent expiration dates:
- April 16, 2033
  ✓
  Drug substance
  ✓
  Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- November 16, 2028 - NEW CHEMICAL ENTITY

More about Truqap (capivasertib)

Patient resources

Truqap drug information

Professional resources

Related treatment guides

Breast Cancer

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

Review this drug

Images

Pill CAV 200 is Truqap 200 mg — Truqap 200 mg (CAV 200)